MedTrace Logo

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

NCT00291187 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2014-10-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.

Conditions

Interventions

DRUG

20 mg VEC-162

20 mg VEC-162

DRUG

50 mg VEC-162

50 mg VEC-162

DRUG

100 mg VEC-162

100 mg VEC-162

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Vanda Pharmaceuticals · Vanda Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291187 on ClinicalTrials.gov